| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (NCT03875313) | Calithera Biosciences, Inc | 2019-05-20 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) (NCT02293980) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-11-25 |
| Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study (NCT06775574) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2014-11-01 |
| Visceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study on Postoperative Survival (NCT06791863) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2014-11-01 |